Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
D 14.50 0.28% 0.04
URGN closed up 0.28 percent on Monday, March 18, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Fell Below Previous Day's Low about 20 hours ago
1.5x Volume Pace about 21 hours ago
Down 3% about 21 hours ago
Down 2 % about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

UroGen Pharma Ltd. Description

UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Oab Botulinum Toxin Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder

Is URGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.13
52 Week Low 7.75
Average Volume 301,355
200-Day Moving Average 14.69
50-Day Moving Average 16.63
20-Day Moving Average 17.43
10-Day Moving Average 16.76
Average True Range 1.10
RSI (14) 32.89
ADX 27.44
+DI 11.27
-DI 34.29
Chandelier Exit (Long, 3 ATRs) 16.58
Chandelier Exit (Short, 3 ATRs) 17.12
Upper Bollinger Bands 20.12
Lower Bollinger Band 14.74
Percent B (%b) -0.04
BandWidth 30.88
MACD Line -0.47
MACD Signal Line 0.05
MACD Histogram -0.5251
Fundamentals Value
Market Cap 447.56 Million
Num Shares 30.9 Million
EPS -4.14
Price-to-Earnings (P/E) Ratio -3.50
Price-to-Sales 7.77
Price-to-Book 16.05
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.63
Resistance 3 (R3) 15.53 15.06 15.44
Resistance 2 (R2) 15.06 14.77 15.11 15.38
Resistance 1 (R1) 14.78 14.59 14.88 14.88 15.32
Pivot Point 14.30 14.30 14.35 14.35 14.30
Support 1 (S1) 14.02 14.01 14.12 14.12 13.68
Support 2 (S2) 13.55 13.84 13.60 13.62
Support 3 (S3) 13.27 13.55 13.56
Support 4 (S4) 13.37